ESMO 2022 journaal | Mammacarcinoom

In dit journaal bespreken Dr. Marleen Kok en dr. Willemien Menke samen met presentator Inge Diepman het belangrijkste nieuws van ESMO 2022 op het gebied van mammacarcinoom.

Bent u vooral geïnteresseerd in een specifiek onderwerp? Maak dan gebruik van onze hoofdstukindeling. Deze is te herkennen aan de drie streepjes rechtsonder in de videospeler.

De volgende abstracts komen in dit journaal aan bod:

Vroegstadium mammacarcinoom

• Dose-dense adjuvant chemotherapy in early-stage breast cancer patients : end-of-study results from a randomised, phase 3 trial of the Gruppo Italiano Mammella (GIM).
• Extended Adjuvant Aromatase Inhibition After Sequential Endocrine Therapy: final results of the phase 3 DATA trial
• Impact of age, Recurrence Score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials

CDK4/6-remming in de gemetastaseerde hormoongevoelige setting

• MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
• Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): a randomized, open-label, phase 2 trial

Tweede- en derdelijnsbehandeling hormoongevoelig mammacarcinoom

• Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study
• Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
• AMEERA-3, a Phase 2 study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
• Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Triple negatief mammacarcinoom

• Primary endpoint analysis of a randomized phase 2 of darolutamide or capecitabine in patients with triple-negative androgen receptor positive advanced breast cancer (UCBG3-06 START trial)
• Primary endpoint results of SYNERGY, a randomized phase 2 trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC).
• HRQoL With Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy, Followed by Adjuvant Pembrolizumab vs Placebo for Early-Stage TNBC: Results From KEYNOTE-522
• Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial

Bekijk hier het volledige overzicht van onze ESMO 2022 journaals en interviews.

Wij zijn benieuwd wat u van dit programma vindt en stellen het op prijs als u het evaluatieformulier invult. Gemiddeld duurt het 2 minuten om de enquête te vullen.